Immunotherapies targeting PD1/PD‐L1, which can reverse immune tolerance and yielded remarkable clinical responses, have been widely studied in tumors.27, 28, 29, 30 Zheng et al31 indicated that the balance of Th17 cells and Treg cells was broken in patients who underwent gastric cancer resection, increasing the function of the PD‐1/PD‐L1 axis. This evidence concerns the gene CD274 and gastric cancer.